Avastin-eluting stent: long-term angiographic and clinical follow up.

Abstract

The detection of atheromatous lesions in patients with coronary artery disease is related to neovascularisation, since it is associated with the presence of a dense network of vasa vasorum in the vascular wall. The increased density of vasa vasorum causes destabilisation of the atheromatous plaque. The safety and efficacy of a stent coated with bevacizumab, a monoclonal antibody for vascular endothelial growth factor have been established at both the experimental and the clinical level. We present the case of a patient with acute myocardial infarction and significant stenosis in the mid-section of the left anterior descending coronary artery, treated by implantation of a bevacizumab-coated stent. A coronary angiographic examination 2 years later showed patent coronary arteries with a well-preserved angioplasty result in the anterior descending artery. This is the first report of findings beyond six-month follow up of this type of stent and represents the first clinical and angiographic proof of its long-term efficacy.

• Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Elli Stefanadi, Eleftherios Tsiamis, Manolis Vavuranakis, Nicholas Kipshidze
• Journal: Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese (Hellenic J Cardiol) 2008 May-Jun Vol. 49 Issue 3 Pg. 188-90 ISSN: 1109-9666 [Print] Netherlands
• PMID: 18543649 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Endothelial Growth Factors
• Bevacizumab

Topics

• Angiogenesis Inhibitors
• Angioplasty, Balloon, Coronary
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Coronary Angiography
• Coronary Artery Disease (diagnostic imaging, therapy)
• Drug-Eluting Stents
• Endothelial Growth Factors
• Humans
• Male
• Middle Aged
• Vascular Patency